Penbraya (PF-06886992) / Pfizer - LARVOL DELTA

Preventing Meningococcal Disease in US Adolescents and Young Adults Through Vaccination. (PubMed, Infect Dis Ther) - "ARTEMIS proposed strategies to address knowledge gaps and access barriers at the HCP, parent/AYA, and educational institution/policymaker levels. Alternative vaccination schedules using a recently approved MenABCWY vaccine that provides protection against all five major serogroups may simplify meningococcal vaccination and increase coverage."

Journal • Review • Infectious Disease • Meningococcal Infections

Penmenvy - a second pentavalent meningococcal vaccine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Meningococcal Infections

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial. (PubMed, Hum Vaccin Immunother) - "Immune responses for MenB test strains were higher with MenABCWY versus 4CMenB+MenACWY-TT and generally similar with 60 µg and 120 µg MenB-fHbp+MenACWY-TT or MenABCWY. Based on the limited results, the consistency of MenB immune responses with 60 µg and 120 µg MenB-fHbp suggests doses < 60 µg could be investigated to assess whether a more acceptable safety profile in conjunction with beneficial immune responses is possible in 2-month-old infants."

Clinical • Journal • P2b data • Infectious Disease • Meningococcal Infections • Pediatrics

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose. (PubMed, Vaccine) - P3 | "Immune responses remained high for MenA/C/W/Y and above baseline for MenB through 4 years after the MenABCWY primary series, with robust responses for all 5 serogroups observed following a booster. The MenABCWY booster had an acceptable safety and tolerability profile consistent with the primary series. NCT03135834."

Clinical • Journal • Infectious Disease • Meningococcal Infections

Preferences of US adolescents and parents for vaccination against invasive meningococcal disease. (PubMed, Vaccine) - "Level of protection and risk of mild-to-moderate side effects were the most important vaccine attributes. Adding a pentavalent vaccine alternative increased WTV particularly among adults, individuals who were vaccine-hesitant, and individuals without health insurance."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections

The impact of regional disparities on the availability of meningococcal vaccines in the US. (PubMed, BMC Public Health) - "Overall, the results show that MenACWY has greater stock relative to MenB across the US. This difference is exacerbated in vulnerable areas without school entry requirements for vaccination and results in inequity of vaccine availability. Beyond state-level policy and SES differences, SCDM recommendations may be a contributing factor, although this was not directly assessed by our model."

Journal • Infectious Disease • Meningococcal Infections

UTILITY AND PUBLIC HEALTH IMPACT OF A PENTAVALENT MENINGOCOCCAL VACCINE (ESPID 2024) - "Results The MenABCWY vaccine (Penbraya TM ), comprising MenACWY (Nimenrix ® ) and MenB (Trumenba ® ), was recently licensed in the United States for 10−25-year-olds as a 2-dose schedule taken 6 months apart. Clinical data and extended interval data between doses of MenABCWY, combined with evolving IMD epidemiology data in adolescents and young adults, should be considered to develop recommendations that will simplify vaccine implementation, increase coverage, and optimize disease prevention. Funding: Pfizer"

Infectious Disease • Meningococcal Infections

Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. (PubMed, MMWR Morb Mortal Wkly Rep) - "Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and two serogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer Inc.]), are licensed and available in the United States and have been recommended by CDC's Advisory Committee on Immunization Practices (ACIP). Different manufacturers' serogroup B-containing vaccines are not interchangeable; therefore, when MenACWY-TT/MenB-FHbp is used, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.). This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-TT/MenB-FHbp."

Journal • Immunology • Infectious Disease • Meningococcal Infections • Primary Immunodeficiency

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (clinicaltrials.gov) - P2 | N=326 | Terminated | Sponsor: Pfizer | Phase classification: P2b ➔ P2

Phase classification • Infectious Disease • Meningococcal Infections

Penbraya: A pentavalent meningococcal vaccine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Meningococcal Infections

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules (clinicaltrials.gov) - P2 | N=309 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | Phase classification: P2b ➔ P2

Phase classification • Trial completion • Infectious Disease • Meningococcal Infections

A Phase 2b Study to Describe the Safety and Immunogenicity of MenABCWY in Healthy Infants 2 and 6 Months of Age (clinicaltrialsregister.eu) - P2; N=550; Sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Clinical • New P2 trial • Dermatology • Infectious Disease